CTNNA1 and ovarian cancer: Furthermore, our results focused on methylation status of CAMs and revealed a 3-gene (CTNNA1, DLC1, MFAP4) methylation signature with a prognostic significance that may provide a new biomarker for personalized treatment in ovarian cancer.